Thanks Proff, I tried to read it all and became boss eyed, so I skipped to anything relevant to my genotype. That was a longgggggggggggggggggggggggggggggggggggggggggg read.

That has set me up nicely to sleep. :D

Thanks for the info. x

Thank you, thank you very much........         228 pgs is the short version, lol! Always good to share these encouraging guideline updates. I'm continually amazed at how fast the R&D is moving now. Look at Gilead's recent statement, they're moving on to HBV research because they think Epclusa w/Vox is the end game of treatment. When I finished treatment in December 2013, these drugs were nothing but trial numbers and unknowns. The cure is upon us....

Signed, The Professor  (Ha, ha!)

I third that nomination! So let it be written, so let it be done!   * Its only 228 pages too

SF

... And So Proclaimed, "Prof. Tig of the interweb" ...

... aka "Doctor Decipherer".

D

I hereby decree that Tig56 is bestowed with an honorary chair in online hepatitis C research from the University of Web.

Henceforth thou shalt be called Prof. Tig of the interweb.

Thanks Tig,

It's great to have the LATEST Guidelines ... thanks for the update!!

Dave

Updated HCV guidelines have been released by the AASLD (American Assoc. for the Study of Liver Disease) and the IDSA (Infectious Disease Society of America).

Multiple sections of the guidance posted on HCVguidelines.org have been revised to reflect the FDAs approval of Epclusa (sofosbuvir/velpatasvir, Gilead Sciences) for all chronic HCV genotypes in adults. The combination drug was approved in June for patients with HCV regardless of cirrhosis status.

We believe that the updated recommendations will help caregivers with regimen choice, not only in common treatment scenarios, but will also importantly provide guidance in cases where randomized trial data or specific FDA labeling may be lacking, Raymond Chung, MD, co-chair of the HCV Guidance panel, said in the release. (Healio/HCV Next)

HCV Guidelines Update July 2016